Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.

ONTRUZANT^® (trastuzumab-dttb) is FDA Approved

HCPCS Code Q5112 effective July 1, 2019